Cynata Therapeutics Limited (AU:CYP) has released an update.
Cynata Therapeutics Limited, a clinical-stage biotech firm, has announced continued progress in multiple clinical trials, including for acute graft-versus-host disease and diabetic foot ulcers, with promising initial results and publications in Nature Medicine. They also reported a healthy cash balance and anticipate further developments in a kidney transplantation trial slated to begin in Q3 2024. The company remains poised for significant clinical advancements through the second half of 2025.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.
